Francisco J. Hernandez-Ilizaliturri MD
Francisco J. Hernandez-Ilizaliturri
MD
Clinical Associate Professor of Medicine
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Internal Medicine; Medical Oncology
Education and Training:
- Fellowship, Medicine & Immunology, Roswell Park Cancer Institute (2003)
- Fellowship, Medical Oncology, University at Buffalo/Roswell Park Cancer Institute (2002)
- Residency, Internal Medicine, University at Buffalo/Millard Fillmore Hospitals (1999)
- Residency, Internal Medicine, Instituto Medico del Seguro Social (1996)
- MD, Internal Medicine, The Instituto Tecnologico y de Estudios Superiores de Monterrey (1995)
Employment:
- Clinical Associate Professor, Medicine, Roswell Park Comprehensive Cancer Center Jacobs School of Medicine & Biomedical Sciences (2016-present)
- Assistant Professor of Immunology, Medicine, University at Buffalo/Roswell Park Cancer Institute Jacobs School of Medicine & Biomedical Sciences (2006-present)
- Assistant Professor of Medicine, Medicine, University at Buffalo, The State University of New York Jacobs School of Medicine & Biomedical Sciences (2004-present)
- Assistant Professor of Medicine, Medicine, Roswell Park Cancer Institute/University at Buffalo (2003-present)
- Member, Tumor Immunology Program, Roswell Park Cancer Institute (2003–2006)
- Physician Scientist, Roswell Park Cancer Institute (2002–2003)
Awards and Honors:
- Patient Service Award, Leukemia & Lymphoma Society (2011)
- Best Scientific Report, Roswell Park Cancer Institute (2002)
- Award of Excellence Scholarly Exchange Day, University at Buffalo (2002)
- Honorable Mention in Medicine, Instituto Tecnologico y de Estudios Superior (1995)
Grants and Sponsored Research:
- July 2013–June 2017
Targeting the P13K/Akt Pathway in Therapy Resistant B-cell NHL
St. Baldricks Foundation
Role: Consultant
$445,000 - July 2015–June 2016
Targeted Therapy in Resistant B-NHL
National Cancer Institute
Role: Consultant - July 2014–June 2015
Targeted Therapies in B-NHL
National Cancer Institute
Role: Consultant - June 2009–May 2014
Targeting the proteasome to overcome therapy resistance in B-NHL.
NIH
Role: Co-Investigator - March 2011–March 2012
Lymphoma translational research infrastructure.
JPWCC / RPCI
Role: Principal Investigator
Journal Articles:
- Torka P, Mavis C, Kothari S, Belliotti S, Gu J, Sundaram S, Barth MJ, Hernandez-Ilizaliturri FJ. (2020) Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma. eJHaem (Apr).
- Torka P, Barth MJ, Ferdman R, Hernandez-Ilizaliturri FJ. (2019) Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies. Curr Hematol Malig Rep (Oct), 14(5): 426-438.
- Runckel K, Barth MJ, Mavis C, Gu JJ, Hernandez-Ilizaliturri FJ. (2018) The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma. Blood Adv (Dec), 2(23): 3516-3525.
- Bhatti M, Ippolito T, Mavis C, Gu J, Cairo MS, Lim MS, Hernandez-Ilizaliturri FJ, Barth MJ. (2018) Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. Oncotarget (Apr), 9(31): 21820-21830.
- Gu JJ, Singh A, Xue E, Mavis C, Barth MJ, Yanamadala V, Lenz P, Grau M, Lenz G, Czuczman MS, Hernandez-Ilizaliturri FJ. (2017) Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. Oncotarget (Dec), 9(3): 4020-4033.
- Evren S, Khoury T, Neppalli V, Cappuccino H, Hernandez-Ilizaliturri FJ, Kumar P. (2017) Breast Implant-Associated Anaplastic Large Cell Lymphoma (ALCL): A Case Report. Am J Case Rep (May), 18: 605-610.
- Czuczman NM, Barth MJ, Gu J, Neppalli V, Mavis C, Frys SE, Hu Q, Liu S, Klener P, Vockova P, Czuczman MS, Hernandez-Ilizaliturri FJ. (2016) Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. Blood (Mar), 127(9): 1128-1137.
- Barth MJ, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. (2015) Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma. Clin Cancer Res (Oct), 21(19): 4391-4397.
- Frys S, Simons Z, Hu Q, Barth MJ, Gu JJ, Mavis C, Skitzki J, Song L, Czuczman MS, Hernandez-Ilizaliturri FJ. (2015) Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Br J Haematol (May), 169(4): 506-519.
- Przespolewski AC, Przespolewski E, Hernandez-Ilizaliturri FJ. (2015) Ibrutinib in the Management of B-cell Malignancies. Journal of Targeted Therapies (May).
- Gu JJ, Hernandez-Ilizaliturri FJ, Mavis C, Czuczman NM, Deeb G, Gibbs J, Skitzki JJ, Patil R, Czuczman MS. (2013) MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical mo. Anticancer Drugs (Nov), 24(10): 1030-1038.
- Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, Czuczman NM, Mavis C, Skitzki JJ, Czuczman MS. (2013) The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br J Haematol (Sep), 162(5): 657-669.
- Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS. (2012) Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol (Feb), 156(4): 490-498.
- Vaidyanathan G, Ngamphaiboon N, Hernandez-Ilizaliturri FJ. (2011) Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation: case series and a review of the literature. Ann Hematol (Aug), 90(8): 955-962.
- Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri FJ, Bambach BJ, Battiwalla M, Padmanabhan S, McCarthy PL, Hahn T. (2008) Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplant (Apr), 41(7): 613-619.
Abstracts:
- Barth MJ, Mavis C, Czuczman NM, Frys S, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. (2013) MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo. (Dec) 647-647
- Frys S, Skomra A, Czuczman NM, Mavis C, Rolland D, Lim M, Tiwari A, Cairo MS, Czuczman MS, Hernandez-Ilizaliturri FJ, Barth MJ. (2013) The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models. (Dec) 5144-5144
- Miller J, Barth MJ, Mavis C, Tsai P, Klener P, Hernandez-Ilizaliturri FJ, Czuczman MS. (2012) Ublituximab (TGTX-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab-Resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In Vitro and In Vivo Models. (Nov) 2756-2756
- Czuczman NM, Barth MJ, Dawar R, Mavis C, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. (2012) Evaluation of the Anti-Tumor Activity of MLN4924 (a Novel NEDD8 Activating Enzyme Inhibitor) in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma. (Nov) 2761-2761
- Barth MJ, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS. (2012) MLN4924, an Investigational Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Inhibits NF-kB Activity and Induces G1 Cell Cycle Arrest and Apoptosis in Pre-Clinical Models of Hodgkin Lymphoma (HL). (Nov) 3717-3717
- Barth MJ, Pendurti G, Tsai P, Mavis C, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. (2012) Ofatumumab (OFA) is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity In Vitro and In Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models. (Nov) 2757-2757
- Frys S, Barth MJ, Gu J, Mavis C, Gibbs JF, Czuczman MS, Hernandez-Ilizaliturri FJ. (2012) Etinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor is Active in B-Cell Lymphoma Pre-Clinical Models and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors. (Nov) 1649-1649
- Dawar R, Barth MJ, Mavis C, Skitzki J, Czuczman MS, Klener P, Hernandez-Ilizaliturri FJ. (2012) Evaluation of MLN4924, an Investigational NEDD8-Activating Enzyme (NAE) Inhibitor, as a Novel Targeted Agent with Single-Agent Antitumor Activity in Mantle Cell Lymphoma (MCL) and Hodgkin Lymphoma Pre-Clinical Models. (May)
- Barth MJ, Pendurti G, Mavis C, Czuczman NM, Gibbs JF, Deeb G, Czuczman MS, Hernandez-Ilizaliturri FJ. (2011) Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) in Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived From Patient Tumor Samples. (Nov) 4972-4972
- Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. (2010) Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenograft. (Nov) 3917-3917
- Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. (2010) Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents in Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenograft. (Nov)
- Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. (2010) Activity of Ofatumumab (OFA), a Fully Human Monoclonal Antibody Targeting CD20, Against Rituximab (RTX)-Sensitive (RSCL) and Rituximab-Resistant Cell Lines (RRCL), In Vivo, and Primary Tumor Cells Derived from Patients with B-Cell Lymphoma. (May) 8095-8095
Professional Memberships:
- American Association for Cancer Research Member (2003–present)
- American Society of Hematology (2001–present)
- American Society of Clinical Oncology (1999–present)
- American College of Physicians (1996–1999)
- American Medical Association (1996–1999)